About us

The team behind NeoTargets has long-standing expertise in cancer biology, drug target discovery and drug discovery.

We have established a pioneering oncotarget discovery platform, for systematic identification and prioritisation of new and underexplored oncology targets.

Neo targets didn’t emerge in isolation

NeoTargets is closely connected to Karolinska Institutet in Stockholm and that is not a coincidence. Our scientific founders, Julian Walfridsson and Mikael Altun, have spent decades as faculty at Karolinska Institutet in Stockholm, collaborating with researchers, spinouts, and industry partners, bridging basic science and therapeutic development.

Karolinska is one of the most famous universities in Europe, known for top-tier biomedical research (and also where the faculty decides the Nobel Prize in Physiology and Medicine).

Karolinska is a driver of translational innovation, where scientific insights are continuously turned into clinical impact.

In oncology, precision begins with understanding. And few institutions understand cancer biology as good as Karolinska.

We identify, operate and collaborate on drug development programs and out-license them at the preclinical stage to the biotech or pharma partners.

Using our platform we generate preclinical proof-of-concept for:

• Targets
• Target groups
• Target/drug candidate combinations

Thereby generating a diverse portfolio of assets.

At various stages of development, assets will be:

• Partnered
• Out-licensed
• Sold

This approach allows us to explore different mechanisms of action and therapeutic strategies for a variety of cancers and provide optimal opportunities to partners or licensees to advance the drug candidates further and bring them to market.

Out discovery platform is modality independent which give us the possibility to identify and validate targets for a variety of modalities.

We collaborate with a variety of companies and research groups, working with different technologies, to bring forth new drug candidates.

• Small molecules
• FBDD
• AI driven protein design
• PROTACS

Collaboration agreements can be flexible depending on need and program. From upfront payments, milestones or to shared asset ownership.

Management

Experienced leadership spanning commercialization, cancer biology, translational validation and partnering.